Melanoma Drug’s Link to Other Skin Cancers Identified (HealthDay)

HealthDay – WEDNESDAY, Jan. 18 (HealthDay News) — The recently approved drug
vemurafenib (Zelboraf) has been hailed as a breakthrough in the treatment
of melanoma, the deadliest form of skin cancer. But roughly one-quarter of
patients who take the medication develop a troublesome side effect:
secondary skin cancers called squamous cell carcinomas.